Comparison of high-density lipoprotein cholesterol to apolipoprotein A-I and A-II to predict coronary calcium and the effect of insulin resistance.

[1]  R. Frikke-Schmidt.  Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. , 2010, Atherosclerosis.

[2]  P. Barter,et al.  Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. , 2009, Archives of internal medicine.

[3]  Robert Dufour,et al.  Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .

[4]  M. Reilly,et al.  Apolipoprotein B but not LDL Cholesterol Is Associated With Coronary Artery Calcification in Type 2 Diabetic Whites , 2009, Diabetes.

[5]  Gordon H Guyatt,et al.  Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis , 2009, BMJ : British Medical Journal.

[6]  N. Wareham,et al.  High-Density Lipoprotein Particle Size and Concentration and Coronary Risk , 2009, Annals of Internal Medicine.

[7]  Nikolaus Marx,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. , 2008, The American journal of cardiology.

[8]  D. Rader,et al.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. , 2008, Journal of the American College of Cardiology.

[9]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[10]  R. Luben,et al.  Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease , 2007, Circulation.

[11]  A. Biggeri,et al.  Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study , 2006, Diabetologia.

[12]  Richard A. Kronmal,et al.  Distribution of Coronary Artery Calcium by Race, Gender, and Age: Results from the Multi-Ethnic Study of Atherosclerosis (MESA) , 2005, Circulation.

[13]  M. Flather,et al.  The association of coronary calcium score and conventional cardiovascular risk factors in Type 2 diabetic subjects asymptomatic for coronary heart disease (The PREDICT Study) , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[14]  A. Localio,et al.  Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. , 2004, Atherosclerosis.

[15]  A. Evans,et al.  Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Y. Arad,et al.  Association of Multiple Risk Factors and Insulin Resistance With Increased Prevalence of Asymptomatic Coronary Artery Disease by an Electron-Beam Computed Tomographic Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[17]  A. Sharrett,et al.  Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.

[18]  C. Langefeld,et al.  Familial aggregation of coronary artery calcium in families with type 2 diabetes. , 2001, Diabetes.

[19]  H. Hecht,et al.  Relation of coronary artery calcium identified by electron beam tomography to serum lipoprotein levels and implications for treatment. , 2001, The American journal of cardiology.

[20]  P. Elwood,et al.  Apolipoproteins A–I, A–II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly Study , 2000, European journal of clinical investigation.

[21]  W. Mack,et al.  The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[22]  M. Taskinen,et al.  HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. , 1995, Circulation.

[23]  D. Rader,et al.  Quantitation of Plasma Apolipoproteins in the Primary and Secondary Prevention of Coronary Artery Disease , 1994, Annals of Internal Medicine.

[24]  Hao Li,et al.  Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[25]  J. Buring,et al.  Decreased HDL2 and HDL3 Cholesterol, Apo A‐I and Apo A‐II, and Increased Risk of Myocardial Infarction , 1992, Circulation.

[26]  P. Barter,et al.  High-density lipoproteins and coronary heart disease. , 1991, Journal of cardiovascular risk.

[27]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[28]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[29]  J. Albers,et al.  Precipitation of 125 I-labeled lipoproteins with specific polypeptide antisera. Evidence for two populations with differing polypeptide compositions in human high density lipoproteins. , 1971, Biochemistry.

[30]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[31]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.